Portal:AOP/Mission

From WikiPathways

(Difference between revisions)
Jump to: navigation, search
Current revision (11:06, 19 December 2017) (view source)
 
(One intermediate revision not shown.)
Line 4: Line 4:
The proposed list of the first set of AOPs to be created, some are more defined than others:
The proposed list of the first set of AOPs to be created, some are more defined than others:
-
* Decrease of lysosomal phospholipase activity leads to phospholipidosis
+
* Chemical-induced bile duct obstruction leads to liver failure
-
* Immune-mediated liver injury
+
* Chemical-induced bile duct obstruction leads to nephrotoxicity
-
* Reduced mitochondrial activity leads to cholestasis
+
* Inhibition of N-linked glycosylation leads to liver injury
-
* Liver fibrosis
+
* Mitochondrial complex inhibition leading to liver injury
-
* Unfolded protein response-mediated liver toxicity
+
-
* Increased ROS levels lead to hepatotoxicity
+
* Inhibition of mitochondrial complex I of nigra-striatal neurons leads to parkinsonian motor deficits
* Inhibition of mitochondrial complex I of nigra-striatal neurons leads to parkinsonian motor deficits
-
* Decreased ATP production leads to neurodegeneration
 
* Peripheral neuropathy caused by microtubule interacting drugs
* Peripheral neuropathy caused by microtubule interacting drugs
* Oxidative reactivity leads to chemical-induced fanconi syndrome
* Oxidative reactivity leads to chemical-induced fanconi syndrome
-
* Oxidative reactivity leads to acceleration of chronic kidney disease
+
* Binding to complex I of the electron transport chain leading to chemical-induced Fanconi syndrome
-
* Compound accumulation via Megalin/Cubilin uptake leads to acute and chronic kidney disease
+
* Intracellular accumulation of chemicals via the megalin/cubulin system leading to tubulonephritis
-
* Renal proximal tubular uptake via organic cation transporters leads to...
+
* Oxidant-induced pulmonary emphysema
-
* Oxidative stress leads to COPD
+
* α-diketone-induced bronchiolitis obliterans
-
* Activation of Smad signaling leads to pulmonary fibrosis
+
-
* Impaired HDAC leads to limbosacral spina bifida
+
* HDAC inhibition leads to neural tube defects
* HDAC inhibition leads to neural tube defects
-
* Cyt p450 inhibition leads to Feminization and Masculinization
+
* Cyp17 inhibition leads to undescended testes
-
* Estrogen/androgen ...
+
* Oxidative stress-induced liver injury
-
* Bone malformation
+
* IKK complex inhibition leads to liver failure
-
* Oxidative stress-induced hepatoxicity
+
-
* Inflammatory cytokine-induced cell death
+
* HDAC inhibition leads to impaired craniofacial development
* HDAC inhibition leads to impaired craniofacial development

Current revision

The purpose of this portal is to create a collection of AOPs on the molecular level for the AOPs that are, or will be created for the EU-ToxRisk program, in which Open PHACTS Foundation (OPF) is responsible for AOP creation. The subjects of the first AOPs are linked to the use cases of the EU-ToxRisk program, and there will be a team of experts involved in the creation of each AOP.


The proposed list of the first set of AOPs to be created, some are more defined than others:

  • Chemical-induced bile duct obstruction leads to liver failure
  • Chemical-induced bile duct obstruction leads to nephrotoxicity
  • Inhibition of N-linked glycosylation leads to liver injury
  • Mitochondrial complex inhibition leading to liver injury
  • Inhibition of mitochondrial complex I of nigra-striatal neurons leads to parkinsonian motor deficits
  • Peripheral neuropathy caused by microtubule interacting drugs
  • Oxidative reactivity leads to chemical-induced fanconi syndrome
  • Binding to complex I of the electron transport chain leading to chemical-induced Fanconi syndrome
  • Intracellular accumulation of chemicals via the megalin/cubulin system leading to tubulonephritis
  • Oxidant-induced pulmonary emphysema
  • α-diketone-induced bronchiolitis obliterans
  • HDAC inhibition leads to neural tube defects
  • Cyp17 inhibition leads to undescended testes
  • Oxidative stress-induced liver injury
  • IKK complex inhibition leads to liver failure
  • HDAC inhibition leads to impaired craniofacial development


Basic strategies and principles for general AOPs are described in this paper:

Villeneuve et al. (2014). Adverse Outcome Pathway (AOP) Development I: Strategies and Principles. Toxicological Sciences PubMed

Personal tools